PHILADELPHIA--(BUSINESS WIRE)--Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that the Company has retired all remaining debt related to convertible debentures issued in October 2003, January 2004 and July 2004. Of the outstanding debt of $4.1 million, only $ 1,643,960 was required to be paid in new funds to retire the debentures, with the balance being covered by other cash and securities already held as collateral for the debentures. At the close of the first quarter of 2007, the Company’s cash and marketable securities totaled $24.6 million.
